On May, 3 The EPS for Regulus Therapeutics Inc. (RGLS) Expected At $-0.15

April 16, 2018 - By Alice Reed

Regulus Therapeutics Inc. (NASDAQ:RGLS) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 1.16. That’s change of 0.19, from 2017Q3’s 1.35. 7 investors sold all, 12 reduced holdings as Regulus Therapeutics Inc. ratio dived. 12 rose positions while 10 funds acquired positions. Funds hold 53.17 million shares thus 9.64% less from 2017Q3’s 58.85 million shares.
Fmr Limited Com stated it has 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Dowling And Yahnke Limited Liability owns 0% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 11,500 shs. Vanguard Gru holds 2.46 million shs or 0% of its capital. Quantitative Investment Management Limited Liability Corporation has 45,800 shs. Washington Commercial Bank accumulated 0% or 155 shs. Millennium Ltd Liability Company has invested 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). State Street Corporation holds 0% or 47,869 shs. Barclays Public Llc reported 89 shs. Meeder Asset Mngmt Inc stated it has 8,981 shs or 0% of all its holdings. Brookstone Mgmt holds 13,200 shs. Susquehanna Group Ltd Liability Partnership invested in 32,631 shs. Manufacturers Life Insurance Co The invested 0% of its capital in Regulus Therapeutics Inc. (NASDAQ:RGLS). Nea Mgmt Company Llc owns 10.99 million shs. Mariner Wealth Advsrs Llc holds 37,400 shs. Northern Tru reported 0% stake.

On May, 3 Regulus Therapeutics Inc. (NASDAQ:RGLS)’s earnings release is anticipated by WallStreet, as reported by RTT. Analysts have anticipation on stock’s earnings per share of $-0.15. That’s up 60.53 % from last year’s $-0.38 earnings per share. 7.14 % negative EPS growth is what Wall Street’s predicts after $-0.14 reported EPS last quarter. On during the last trading session the stock increased $0.0169 or 2.64%, reaching $0.6569.Regulus Therapeutics Inc. has volume of 6,070 shares. Since April 16, 2017 RGLS has declined 52.76% and is downtrending. The stock underperformed the S&P 500 by 64.31%.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Coverage

In total 5 analysts cover Regulus Therapeutics (NASDAQ:RGLS). “Buy” rating has 2, “Sell” are 0, while 3 are “Hold”. 40% are bullish. 9 are the (NASDAQ:RGLS)’s analyst reports since November 8, 2017 according to StockzIntelligence Inc. The company rating was maintained by Wedbush on Thursday, February 8. On Wednesday, December 20 the stock has “Buy” rating by Wedbush. On Monday, March 12 Wedbush maintained Regulus Therapeutics Inc. (NASDAQ:RGLS) rating. Wedbush has “Buy” rating and $3.0 target. On Wednesday, November 8 BMO Capital Markets maintained Regulus Therapeutics Inc. (NASDAQ:RGLS) rating. BMO Capital Markets has “Market Perform” rating and $1 target. On Monday, December 11 the stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) has “Buy” rating given by Wedbush. In Thursday, March 8 report BMO Capital Markets maintained the stock with “Market Perform” rating. On Tuesday, March 27 FBR Capital initiated the shares of RGLS in report with “Hold” rating.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States.The firm is worth $68.29 million. The firm uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides.Last it reported negative earnings. The Company’s clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: